|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, HES/Leukemia, 4q12 Rearrangement, TC
Test CodeCPT Codes
88271, 88275<br>Restricted Client Code - Tech Only
Preferred Specimen
Minimum Volume
Other Acceptable Specimens
Instructions
Clinical history/reason for referral is required with test order. Prior therapy and transplant history should be provided with test order.
Bone marrow: 1-3 mL in transport medium (preferred) or sodium heparin tube.
3-5 mL whole blood in sodium heparin tubes. Green, dark/ royal blue or tan top tubes are acceptable containers for this test.
Formalin-fixed, paraffin-embedded block and fresh tumor tissue samples are also acceptable.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Transport Temperature
Specimen Stability
Methodology
Fluorescence in situ Hybridization
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Clinical Significance
100-200 interphase nuclei are examined microscopically for the rearrangements of 4q12.
FIP1L1-PDGFRa fusion (rearrangement of 4q12; interstitial deletion of CHIC2 region) is observed in diverse eosinophilia-associated hematologic disorders. The cases with FIP1L1-PDGFRa fusion show an excellent response to the tyrosine kinase inhibitor imatinib mesylate (Metzgeroth et al., 2007).